Introduction: About 25% of ovarian cancers can be classified as hereditary. Of these, 80-90% are correleted with the Hereditary Breast-Ovarian Cancer Syndrome (HBOC), which is linked to BRCA 1/2 genes mutations. Our study was set up to study the BRCA-mutation incidence in Apulian population affected with ovarian cancer and to understand the characteristics of the ovarian disease BRCAmut-related. Results: One hundred and five Apulian patients affected by ovarian cancer with serous high grade histotype, were collected. Of these, 39% were carriers of BRCA 1/2 mutation. BRCAmut patients present a lower median age of onset, a lower percentage of neoplasms in advanced stages and a lower mortality than wild type patients; BRCAmutated patients have...
BRCA testing is recommended in all Ovarian Cancer (OC) patients, but the optimal approach is debated...
Objectives: To evaluate the accuracy of algorithms for predicting BRCAI/2 germ-line mutation carrier...
Objectives: Assessing the combined impact of mutation position, regarding the ovarian cancer cluster...
Introduction: About 25% of ovarian cancers can be classified as hereditary. Of these, 80-90% are cor...
BACKGROUND: It is believed that BRCA1 and BRCA2 germline mutations account for the majority of hered...
Funding Information: This work was supported by State Research Program “Biomedicine for the public h...
PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and...
BACKGROUND: In the last decades, there have been several efforts to clarify the role of BRCA mutatio...
More than one-fifth of ovarian tumors have hereditary susceptibility and, in about 65\u201385% of th...
Background: Identifying female carriers of BRCA1 and BRCA2 mutations is imperative ...
At least 10% of all ovarian cancers are estimated to have a hereditary background. Hereditary breast...
Background: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dis...
Purpose To characterise the prevalence of pathogenic germline mutations in BRCA1 and BRCA2 in famili...
Breast cancer is the most common malignancy in women. Most of the breast cancers are sporadic with n...
BRCA1 and BRCA2 germline mutations contribute to a significant number of familial and hereditary bre...
BRCA testing is recommended in all Ovarian Cancer (OC) patients, but the optimal approach is debated...
Objectives: To evaluate the accuracy of algorithms for predicting BRCAI/2 germ-line mutation carrier...
Objectives: Assessing the combined impact of mutation position, regarding the ovarian cancer cluster...
Introduction: About 25% of ovarian cancers can be classified as hereditary. Of these, 80-90% are cor...
BACKGROUND: It is believed that BRCA1 and BRCA2 germline mutations account for the majority of hered...
Funding Information: This work was supported by State Research Program “Biomedicine for the public h...
PURPOSE: To evaluate the contribution of germline BRCA1 mutations in the incidence of hereditary and...
BACKGROUND: In the last decades, there have been several efforts to clarify the role of BRCA mutatio...
More than one-fifth of ovarian tumors have hereditary susceptibility and, in about 65\u201385% of th...
Background: Identifying female carriers of BRCA1 and BRCA2 mutations is imperative ...
At least 10% of all ovarian cancers are estimated to have a hereditary background. Hereditary breast...
Background: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dis...
Purpose To characterise the prevalence of pathogenic germline mutations in BRCA1 and BRCA2 in famili...
Breast cancer is the most common malignancy in women. Most of the breast cancers are sporadic with n...
BRCA1 and BRCA2 germline mutations contribute to a significant number of familial and hereditary bre...
BRCA testing is recommended in all Ovarian Cancer (OC) patients, but the optimal approach is debated...
Objectives: To evaluate the accuracy of algorithms for predicting BRCAI/2 germ-line mutation carrier...
Objectives: Assessing the combined impact of mutation position, regarding the ovarian cancer cluster...